Glyxambi (empagliflozin and linagliptin)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

July 2016

WARNINGS AND PRECAUTIONS

Ketoacidosis (addition of the following sentence in first paragraph)

Fatal cases listed